The controversy behind PrEP: Part 3 of our four-part series

Is PrEP's promise too good to be true?


In the third of a four-part Daily Xtra series, Nicolas Kazamia looks at the controversy surrounding PrEP. Is it too early to call this drug a game-changer? Or is too much caution costing lives?

In the third part of our series on pre-exposure prophylaxis (PrEP), Daily Xtra looks at the controversy surrounding the HIV prevention drug. While many people are heralding a new chapter in the fight against HIV, others say it’s much too early to claim victory.

In the above video, Nicolas Kazamia speaks with Robert Grant, a senior researcher at the Gladstone Institutes; Alan McCord, from Project Inform; HIV/AIDS prevention workers Tim Ryan and Steve Gibson, from Magnet, a sexual health clinic in San Francisco; and Dale Gluth, the San Francisco Bay area director of the AIDS Healthcare Foundation.

Check back to Daily Xtra for our comprehensive online coverage of PrEP. And follow the conversation on our Facebook page and on Twitter.

In the series

Part 1: Can a pill a day keep HIV away?

Part 2: A condom-free future?

Part 4: If gay man can avoid HIV with a pill, why aren’t they taking it?

Read More About:
Video, Health, Sexual Health, News, HIV/AIDS

Keep Reading

5 things to know about Jonathan Pedneault

What you need to know about Canada’s only openly queer federal political party leader

2025 Canadian federal election: What you need to know

From how and when to register to vote, to the big narratives we’re watching

Carney cabinet cuts Minister for Women and Gender Equality

ANALYSIS: Prime Minister Mark Carney’s new cabinet is down several roles focused on diversity, equity and inclusion

Where does Mark Carney stand on queer and trans issues?

ANALYSIS: The new Liberal leader and prime minister-designate should affirm his party’s stance before going toe to toe with Pierre Poilievre